Collegium Pharmaceutical, Inc. (COLL) Rating Increased to Buy at Zacks Investment Research
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Monday. The firm currently has a $16.00 target price on the specialty pharmaceutical company’s stock. Zacks Investment Research‘s price target points to a potential upside of 13.56% from the company’s current price.
According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “
COLL has been the topic of a number of other research reports. Piper Jaffray Companies set a $14.00 target price on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a research note on Tuesday, July 25th. Jefferies Group LLC reaffirmed a “buy” rating and set a $15.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, October 6th. HC Wainwright reaffirmed a “buy” rating and set a $21.00 target price on shares of Collegium Pharmaceutical in a research note on Wednesday, November 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $25.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, October 6th. Finally, BidaskClub cut shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Two research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $19.33.
Collegium Pharmaceutical (NASDAQ:COLL) traded up $1.38 during midday trading on Monday, hitting $14.09. 2,270,100 shares of the company’s stock were exchanged, compared to its average volume of 453,441. Collegium Pharmaceutical has a 12-month low of $7.37 and a 12-month high of $18.02.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.28. The firm had revenue of $11.95 million for the quarter, compared to analysts’ expectations of $5.31 million. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. The company’s revenue was up 2814.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.13) earnings per share. sell-side analysts expect that Collegium Pharmaceutical will post -2.63 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This story was first posted by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.watchlistnews.com/collegium-pharmaceutical-inc-coll-rating-increased-to-buy-at-zacks-investment-research/1701128.html.
Institutional investors have recently modified their holdings of the stock. American International Group Inc. grew its stake in shares of Collegium Pharmaceutical by 27.8% in the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock worth $100,000 after purchasing an additional 2,163 shares during the last quarter. Voya Investment Management LLC acquired a new position in Collegium Pharmaceutical in the second quarter valued at $125,000. Nationwide Fund Advisors lifted its holdings in Collegium Pharmaceutical by 16.4% in the first quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock valued at $101,000 after buying an additional 1,422 shares during the period. Credit Suisse AG lifted its holdings in Collegium Pharmaceutical by 9.4% in the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock valued at $137,000 after buying an additional 1,173 shares during the period. Finally, UBS Group AG lifted its holdings in Collegium Pharmaceutical by 283.2% in the first quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock valued at $139,000 after buying an additional 10,174 shares during the period. 83.96% of the stock is currently owned by institutional investors.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.